Disclosed is a pyrazole compound of formula (I) where the substituents are as disclosed is the specification. Examples of the compounds are: 5-[2-(4-chloro-phenyl)-1-methyl-vinyl]-1-(2,4-dichloro-phenyl)-4-methyl-1H-pyrazole-3-carboxylic acid [(1S)-1-cyclohexyl-ethyl]-amide, 5-[2-(4-chloro-phenyl)-1-methyl-vinyl]-1-(2,4-dichloro-phenyl)-4-methyl-1H-pyrazole-3-carboxylic acid [(1S)-1-phenyl-ethyl]-amide, 5-[2-(4-chloro-phenyl)-1-methyl-vinyl]-1-(2,4-dichloro-phenyl)-4-methyl-1H-pyrazole-3-carboxylic acid [(1R,2S,4R)-1,3,3-trimethylbicyclo[2.2.1 ]hept-2-yl]-amide. Also disclosed is a pharmaceutical composition comprising a compound of formula (I), a process for making the composition and the use of a compound in the manufacture of a medicament for treating a cannabinoid receptor mediated syndrome such as disorder or disease is related to appetite, metabolism, diabetes, glaucoma-associated intraocular pressure, social and mood disorders, seizures, substance abuse, learning, cognition or memory, organ contraction or muscle spasm, bowel disorders, respiratory disorders, locomotor activity or movement disorders, immune and inflammation disorders, unregulated cell growth, pain management or neuroprotection. The medicament may also comprise an anticonvulsant or a contraceptive agent such as topiramate, analogs of topiramate, carbamazepine, valproic acid, lamotrigine, gabapentin, phenytoin, progestin-only contraceptive, a contraceptive having a progestin component and an estrogen component, or an oral contraceptive optionally having a folic acid component.
